Trending News
News
News
Verenium Announces Organizational Change
The Company strengthens research and development organization, including the pilot and demonstration-scale biofuels operations in Jennings, Louisiana.
News
Zosano Pharma Presents Positive Phase 2 Results of Its Needle-Free Osteoporosis Therapy
Rapid delivery transdermal patch demonstrates increase in lumbar spine and hip bone mineral density.
News
Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Discovery could lead to the development of a next-generation assay to improve diagnosis and treatment of ovarian cancer.
News
Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer
ALN-VSP Represents Company’s First Clinical Program with a Systemically Delivered RNAi Therapeutic.
News
Building a Better Cell Culture System
HHMI researchers creates “intelligent scaffold” for growing human cells that can mimic conditions inside the body better than the standard.
News
NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative Host Nanoweek 2009
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md.
News
Genome Sequencer FLX System Installed at University of Barcelona
The Genome Sequencer FLX will be installed at the Genomics Unit of the Scientific and Technical Services at UB.
News
Compugen Announces Inhibition of Angiogenesis by Novel Peptide
CGEN-25017 peptide antagonist of the Angiopoietin/Tie-2 pathway was predicted using Compugen’s DAC blockers discovery platform.
News
Horizon Discovery Sign Three-Year Collaboration with Genentech
Horizon’s GENESIS™ platform to develop genetically-defined human ‘X-MAN’ cancer models for deployment in Genentech’s research programs.
News
InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center
Collaboration focuses identifying naturally derived modulators by screening IMD’s natural product libraries against targets provided by LDC.
Advertisement